Sign In
Buy KNBIF
$0.0202
+0 (+0%)
At Close: Jul 31, 2026
Kane Biotech Announces First Closing of Private Placement Offering and Extension of Private Placement Offering
08:30am, Monday, 20'th Jan 2025
Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG, Manitoba, Jan. 20, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company”
Kane Biotech Announces $3,000,000 Private Placement Offering
08:30am, Tuesday, 03'rd Dec 2024
WINNIPEG, Manitoba, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) announces today that it intends to undertake a non-brokered
Kane Biotech Announces Third Quarter 2024 Financial Results
04:15pm, Thursday, 28'th Nov 2024
WINNIPEG, Manitoba, Nov. 28, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech”, “Kane” or the “Company”) today announces its third quarter 2024 financial
Kane Biotech Announces Change in US Distribution Partner for revyve™ Antimicrobial Wound Gel
08:30am, Wednesday, 27'th Nov 2024
BioStem Technologies Signs Letter of Intent to Acquire Exclusive US Distribution Rights for revyve™ from ProgenaCare Global BioStem Technologies Signs Letter of Intent to Acquire Exclusive US Distr
Kane Biotech to Release Third Quarter 2024 Financial Results on November 28, 2024
04:30pm, Thursday, 21'st Nov 2024
WINNIPEG, Manitoba, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech”) will release its third quarter 2024 financial results after market close on Thurs
Kane Biotech Announces Health Canada Approval of revyve™ Antimicrobial Wound Gel
01:10pm, Thursday, 14'th Nov 2024
WINNIPEG, Manitoba, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) announces today that it has received Health Canada approval
Kane Biotech Provides Investor Update Following FB Dermatology Acquisition Announcement
08:30am, Thursday, 14'th Nov 2024
President & CEO Marc Edwards and Executive Chair Dr. Robert Huizinga Discuss This Strategic Opportunity President & CEO Marc Edwards and Executive Chair Dr. Robert Huizinga Discuss This Strategic Oppo
Kane Biotech Announces Agreement to Acquire FB Dermatology
01:08pm, Tuesday, 12'th Nov 2024
Transaction will Strengthen Kane's Wound Care and Dermatology Portfolio and Expand Global Commercial Reach Transaction will Strengthen Kane's Wound Care and Dermatology Portfolio and Expand Global Com
Kane Biotech Announces Donation of revyve™ Antimicrobial Wound Gel to Ukraine
08:30am, Wednesday, 23'rd Oct 2024
WINNIPEG, Manitoba, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech” or “Kane”) announces that it is donating 2,000 ounces of revyve™ Antimicrobi
Kane Biotech Announces Exclusive Distribution Agreement With XSONX
08:30am, Thursday, 17'th Oct 2024
WINNIPEG, Manitoba, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech” or “Kane”) announces that it has signed an exclusive five year distribution ag
Kane Biotech to Participate in a Multinational Corporate Collaboration Project
08:30am, Thursday, 03'rd Oct 2024
WINNIPEG, Manitoba, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech”, “Kane” or the “Company”) announces that it is receiving advisory services
Kane Biotech Announces Exercise of Warrants
08:30am, Thursday, 12'th Sep 2024
WINNIPEG, Manitoba, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech” or “Kane”) announces the exercise of an aggregate of 5 million warrants at an
Kane Biotech Announces Second Quarter 2024 Financial Results
04:15pm, Thursday, 29'th Aug 2024
WINNIPEG, Manitoba, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech”, “Kane” or the “Company”) today announces its second quarter 2024 financia
Kane Biotech Announces new DispersinB® Publication in Pathogens and Conference Presentations
08:30am, Thursday, 29'th Aug 2024
WINNIPEG, Manitoba, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech” or “Kane”) announces the publication of a new review article on DispersinB® i
Kane Biotech Announces Distribution Agreement with Qatar Datamation Systems for revyve™ Antimicrobial Wound Gel
08:40am, Wednesday, 28'th Aug 2024
WINNIPEG, Manitoba, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announces that it has signed a three year distribution
